UTAH MEDICAL PRODUCTS INC 10-K — AI Bull & Bear Analysis

The 10-K reveals a company at a crossroads, balancing a pristine balance sheet against a fragile top line. The financial results for 2025 were a mixed bag: while the company remains highly profitable with an operating margin of 29.6%, the 16.1% drop in operating income highlights the impact of losing key customers. The tension for investors lies in whether the loss of PendoTECH and the China distributor represents a temporary setback or a permanent erosion of the company's competitive moat in the OEM space. Ultimately, the 2026 outlook depends on two factors: the successful launch of new biopharma transducer products and the final resolution of the Filshie litigation. If management can stabilize revenues, the removal of the Femcare amortization will provide a genuine boost to the bottom line. However, the precipitous drop in backlog serves as a stark warning that the transition to new revenue streams may be slower and more difficult than management anticipates.